Moderna: Interim Data Show 94.5% Efficacy for Its COVID-19 Vaccine Moderna: Interim Data Show 94.5% Efficacy for Its COVID-19 Vaccine
In a highly anticipated announcement, Moderna releases interim efficacy and safety data from the phase 3 COVE study of its COVID-19 vaccine.Medscape Medical News
Source: Medscape Med Students Headlines - Category: Universities & Medical Training Tags: Infectious Diseases News Alert Source Type: news
More News: COVID-19 | Infectious Diseases | Students | Study | Universities & Medical Training | Vaccines